Determining optimal combination regimens for patients with multiple myeloma

Mahya Aghaee, Urszula Ledzewicz, Michael Robbins, Natalie Bezman, Hearn Jay Cho, Helen Moore

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high-risk disease. In this work, we use a mathematical modeling approach to determine combination therapy regimens that maximize healthy lifespan for patients with multiple myeloma. We start with a mathematical model for the underlying disease and immune dynamics, which was presented and analyzed previously. We add the effects of three therapies to the model: pomalidomide, dexamethasone, and elotuzumab. We consider multiple approaches to optimizing combinations of these therapies. We find that optimal control combined with approximation outperforms other methods, in that it can quickly produce a combination regimen that is clinically-feasible and near-optimal. Implications of this work can be used to optimize doses and advance the scheduling of drugs.

Original languageEnglish
Article number106492
JournalEuropean Journal of Pharmaceutical Sciences
Volume187
DOIs
StatePublished - 1 Aug 2023

Keywords

  • Combination drug regimen
  • Constrained optimization
  • Mathematical model
  • Multiple myeloma
  • Optimal control

Fingerprint

Dive into the research topics of 'Determining optimal combination regimens for patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this